Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Belina Pharma AB has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is associated with 1 distinct examiner and 1 distinct art unit, presenting a single examination context. ENGLISH, CONNOR KENNEDY is the busiest examiner, with 1 pending matter.
The available data supports a targeted prosecution plan for the outstanding pharmaceutical matter. No additional examiner or art-unit assignment is recorded, so counsel can concentrate its review on one set of examination issues. Claim amendments and technical arguments should remain consistent with the disclosure and responsive to the identified examiner’s treatment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769502 | DESLORATADINE FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF GASTROINTESTINAL TRACT CANCERS | ENGLISH, CONNOR KENNEDY | 19d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17769502 | DESLORATADINE FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF GASTROINTESTINAL TRACT CANCERS | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | 19d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBelina Pharma AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Connor Kennedy English has the most, with 1 of Belina Pharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
